

# Programme

## Lupus Academy 10th Annual Meeting: Early Sessions (Online)

### SESSION 1: SLE TREATMENT DILEMMAS

**Tuesday 6th April 2021: 14:00–15:30 hours** CET (UTC+2 Paris, Amsterdam, Berlin)

EDT (UTC-4 New York, Montreal) 8:00 AM – 9:30 AM

CST (UTC+8 Beijing, Manila, Perth) 20:00 – 21:30 hours

<b>Moderators: Andrea Doria (Italy), David Isenberg (UK)</b>	
Should we vaccinate all SLE patients against papillomavirus and herpes zoster? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Sarfaraz Hasni (USA)</i>
Hydroxychloroquine myopathy: cardiac and skeletal muscle toxicity <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Murray Urowitz (Canada)</i>
Low dose aspirin in aPL-positive patients: Are we treating the patient or the doctor? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Denis Wahl (France)</i>

### SESSION 2: THE ROLE OF INTERFERONS IN SLE

**Friday 9th April 2021: 14:00–15:30 hours** CET (UTC+2 Paris, Amsterdam, Berlin)

EDT (UTC-4 New York, Montreal) 8:00 AM – 9:30 AM

CST (UTC+8 Beijing, Manila, Perth) 20:00 – 21:30 hours

<b>Moderators: Zahir Amoura (France), Thomas Dörner (Germany)</b>	
Biology of interferons <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Mary Crow (USA)</i>
How interferonopathies inform SLE pathogenesis <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Yanick Crow (UK)</i>
Interferon inhibition and the future management of SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Eric Morand (Australia)</i>

### SESSION 3: LESSONS LEARNED FROM OTHER DISEASES

**Monday 12th April 2021: 14:00–16:00 hours** CET (UTC+2 Paris, Amsterdam, Berlin)

EDT (UTC-4 New York, Montreal) 8:00 AM – 10:00 AM

CST (UTC+8 Beijing, Manila, Perth) 20:00 – 22:00 hours

<b>Moderators: Eloisa Bonfá (Brazil), Ronald van Vollenhoven (Netherlands)</b>	
Lessons from transplantation: Multitargeted therapy for proliferative lupus nephritis <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Daniel Tak Mao Chan (Hong Kong)</i>
Lessons from ITP: Treatment of refractory thrombocytopenia <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Sacha Zeerleder (Netherlands)</i>
Lessons from scleroderma: Treatment of interstitial lung disease in SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Oliver Distler (Switzerland)</i>
Lessons from RA: RA drug development has advanced at a more rapid pace than SLE: What can we learn from our colleagues? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Ronald van Vollenhoven (Netherlands)</i>

## Friday 16th April 2021

### OPENING SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 13:00–15:15 hours

EDT (UTC-4 New York, Montreal) 7:00 AM – 9:15 AM

CST (UTC+8 Beijing, Manila, Perth) 19:00 – 21:15 hours

<b>Opening</b>	<i>Zahir Amoura (France), Richard Furie (USA)</i>
----------------	---

<b>Keynote</b>	
<b>Moderator: Richard Furie (USA)</b>	
Kidney biopsies in SLE: Too few or too many? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Hans-Joachim Anders (Germany)</i>

<b>Debate: In With the New, Out With Old? Should All Patients with Lupus Nephritis Receive New Generation Therapies in Addition to Established Standard of Care?</b>	
<b>Moderator: Ronald van Vollenhoven (Netherlands)</b>	
The matter of the debate (10 mins)	<i>Ronald van Vollenhoven (Netherlands)</i>
All lupus nephritis patients should be initially managed with <b>both established standard therapies and the new generation drugs</b> (20 mins + 10 mins rebuttal)	<i>Onno Teng (Netherlands)</i>
All lupus nephritis patients should be initially managed with <b>established standard therapies alone</b> (20 mins + 10 mins rebuttal)	<i>Dimitrios Boumpas (Greece)</i>
<b>Voting, Q&amp;A and Discussion (20 Mins)</b>	<i>All</i>

### PLENARY I: NOVEL STRATEGIES FOR OPTIMIZING OUTCOMES IN SLE

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30–17:30 hours

EDT (UTC-4 New York, Montreal) 9:30 AM – 11:30 AM

CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:30 hours

<b>Moderators: Sandra Navarra (Philippines)</b>	
Preventing damage and reducing mortality in lupus. How are we doing? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Murray Urowitz (Canada)</i>
Strategies for minimizing corticosteroid exposure in SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Zahir Amoura (France)</i>
Targeting remission and low disease activity in SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Andrea Doria (Italy)</i>
Lupus treatment in the next decade: The next decade is upon us <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Richard Furie (USA)</i>



# Programme

## OPENING SESSION (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 18:00–20:15 hours

EDT (UTC-4 New York, Montreal) 12:00 PM – 2:15 PM

CST (UTC+8 Beijing, Manila, Perth) 00:00 – 02:15 hours

<b>Opening</b>	<i>Zahir Amoura (France), Richard Furie (USA)</i>
<b>Keynote</b>	
<b>Moderator: Richard Furie (USA)</b>	
Kidney biopsies in SLE: Too few or too many? <b>Recorded Q&amp;A and Discussion (15 Mins)</b>	<i>Hans-Joachim Anders (Germany)</i>
<b>Debate: In With the New, Out With Old? Should All Patients with Lupus Nephritis Receive New Generation Therapies in Addition to Established Standard of Care?</b>	
<b>Moderator: Ronald van Vollenhoven (Netherlands)</b>	
The matter of the debate (10 mins)	<i>Ronald van Vollenhoven (Netherlands)</i>
All lupus nephritis patients should be initially managed with <b>both established standard therapies and the new generation drugs</b> (20 mins + 10 mins rebuttal)	<i>Onno Teng (Netherlands)</i>
All lupus nephritis patients should be initially managed with <b>established standard therapies alone</b> (20 mins + 10 mins rebuttal)	<i>Dimitrios Boumpas (Greece)</i>
<b>Recorded Voting, Q&amp;A and Discussion (20 Mins)</b>	<i>All</i>

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

**Saturday 17th April 2021**

## PLENARY I: NOVEL STRATEGIES FOR OPTIMIZING OUTCOMES IN SLE (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 07:00–09:00 hours

EDT (UTC-4 New York, Montreal) 1:00 AM – 3:00 AM

CST (UTC+8 Beijing, Manila, Perth) 13:00 – 15:00 hours

<b>Moderators: Sandra Navarra (Philippines)</b>	
Preventing damage and reducing mortality in lupus. How are we doing? <b>Recorded Q&amp;A and Discussion (15 Mins)</b>	<i>Murray Urowitz (Canada)</i>
Strategies for minimizing corticosteroid exposure in SLE <b>Recorded Q&amp;A and Discussion (15 Mins)</b>	<i>Zahir Amoura (France)</i>
Targeting remission and low disease activity in SLE <b>Recorded Q&amp;A and Discussion (15 Mins)</b>	<i>Andrea Doria (Italy)</i>
Lupus treatment in the next decade: The next decade is upon us <b>Recorded Q&amp;A and Discussion (15 Mins)</b>	<i>Richard Furie (USA)</i>

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

## CASE STUDY INTERACTIVE WORKSHOPS

CET (UTC+2 Paris, Amsterdam, Berlin) 09:00–10:30 hours

EDT (UTC-4 New York, Montreal) 3:00 AM – 4:30 AM

CST (UTC+8 Beijing, Manila, Perth) 15:00 – 16:30 hours

<b>Moderator/Facilitator: Andrea Doria (Italy)</b>	
Cutaneous lupus	<i>Bernardo Pons-Estel (Argentina), Annegret Kuhn (Germany)</i>
<b>Moderator/Facilitator: Sandra Navarra (Philippines)</b>	
Lupus nephritis	<i>Liz Lightstone (UK), Sandra Navarra (Philippines)</i>
<b>Moderator/Facilitator: David Isenberg (UK)</b>	
Paediatric SLE	<i>Alexandre Belot (France), Rolando Cimaz (Italy)</i>
<b>Moderator/Facilitator: Ricard Cervera (Spain)</b>	
Neuropsychiatric SLE	<i>Ricard Cervera (Spain), Thomas Huizinga (NL)</i>
<b>Moderator/Facilitator: Eloisa Bonfá (Brazil)</b>	
Reproductive health in SLE	<i>Lisa Sammaritano (USA), Rebecca Fischer-Betz (Germany)</i>

## HOT TOPICS: THE ROLE OF COMPLEMENT IN SLE

CET (UTC+2 Paris, Amsterdam, Berlin) 11:00–13:00

EDT (UTC-4 New York, Montreal) 5:00 AM – 7:00 AM

CST (UTC+8 Beijing, Manila, Perth) 17:00 – 19:00 hours

<b>Moderators: Thomas Dörner (Germany), David Isenberg (UK)</b>	
Complement in SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>John Atkinson (USA)</i>
The role of complement and complement inhibition in APS pregnancy <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Jane Salmon (USA)</i>
The interface of the complement and coagulation pathways <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Edward Conway (Canada)</i>
Lessons learned from complement inhibition in ANCA vasculitis <b>Q&amp;A and Discussion (15 Mins)</b>	<i>David Jayne (UK)</i>

# Programme

## PRIME TIME SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 13:30–15:30 hours

EDT (UTC-4 New York, Montreal) 7:30 AM – 09:30 AM

CST (UTC+8 Beijing, Manila, Perth) 19:30 – 21:30 hours

<b>Hot Topics: Highlighting Accomplishments in Lupus Research</b>	
<b>Moderators: Murray Urowitz (Canada), David Isenberg (UK)</b>	
Translational insights into the pathogenesis transforming SLE treatment <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Thomas Dörner (Germany)</i>
Clinical science highlights that are transforming treatment <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Bevra Hahn (USA)</i>

<b>Thieves' Market</b>	
<b>Moderators: Richard Furie (USA), Eloisa Bonfá (Brazil)</b>	
Case in practice: Neither arms NOR legs were feeling well <b>Q&amp;A (10 Mins)</b>	<i>Eduardo Dourado (Portugal)</i>
Case in practice: Born together, best friends together <b>Q&amp;A (10 Mins)</b>	<i>Rinat Raupov (Russia)</i>
Case in practice: A short hi-storiform of time in clinic <b>Q&amp;A (10 Mins)</b>	<i>Saskia Rowson (Australia)</i>
<b>Voting and Panel Discussion</b>	

## CASE STUDY INTERACTIVE WORKSHOPS

CET (UTC+2 Paris, Amsterdam, Berlin) 16:00–17:30 hours

EDT (UTC-4 New York, Montreal) 10:00 AM – 11:30 PM

CST (UTC+8 Beijing, Manila, Perth) 22:00 – 23:30 hours

<b>Moderator/Facilitator: Andrea Doria (Italy)</b>	
Cutaneous lupus	<i>Bernardo Pons-Estel (Argentina), Annegret Kuhn (Germany)</i>
<b>Moderator/Facilitator: Sandra Navarra (Philippines)</b>	
Lupus nephritis	<i>Liz Lightstone (UK), Sandra Navarra (Philippines)</i>
<b>Moderator/Facilitator: David Isenberg (UK)</b>	
Paediatric SLE	<i>Alexandre Belot (France), Rolando Cimaz (Italy)</i>
<b>Moderator/Facilitator: Murray Urowitz (Canada)</b>	
Neuropsychiatric SLE	<i>Ricard Cervera (Spain), Thomas Huizinga (NL)</i>
<b>Moderator/Facilitator: Eloisa Bonfá (Brazil)</b>	
Reproductive health in SLE	<i>Lisa Sammaritano (USA), Rebecca Fischer-Betz (Germany)</i>
<b>Close</b>	

## HOT TOPICS: THE ROLE OF COMPLEMENT IN SLE (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 18:00–20:00

EDT (UTC-4 New York, Montreal) 12:00 PM – 2:00 PM

CST (UTC+8 Beijing, Manila, Perth) 00:00 – 02:00 hours

<b>Moderators: Thomas Dörner (Germany), David Isenberg (UK)</b>	
Complement in SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>John Atkinson (USA)</i>
The role of complement and complement inhibition in APS pregnancy <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Jane Salmon (USA)</i>
The interface of the complement and coagulation pathways <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Edward Conway (Canada)</i>
Lessons learned from complement inhibition in ANCA vasculitis <b>Q&amp;A and Discussion (15 Mins)</b>	<i>David Jayne (UK)</i>

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

**Sunday 18th April 2021**

## PLENARY II: TREATMENT CHALLENGES

CET (UTC+2 Paris, Amsterdam, Berlin) 09:00–11:00 hours

EDT (UTC-4 New York, Montreal) 03:00 AM – 5:00 AM

CST (UTC+8 Beijing, Manila, Perth) 15:00 – 17:00 hours

<b>Moderators: Zahir Amoura (France)</b>	
Treatment of CAPS: Which drugs and in which order? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Marc Pineton de Chambrun (France)</i>
Refractory cutaneous lupus: Use of thalidomide or lenalidomide for refractory lupus skin disease <b>Q&amp;A and Discussion (15 Mins)</b>	<i>François Chasset (France)</i>
Osteonecrosis: Prevention and treatment <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Bernardo Pons Estel (Argentina)</i>
Alveolar hemorrhage <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Ricard Cervera (Spain)</i>

## POSTER SESSION\*: PRESENTATIONS

CET (UTC+2) Paris, Amsterdam, Berlin) 11:30–12:30 hours

EDT (UTC-4 New York, Montreal) 05:30 AM – 06:30 AM

CST (UTC+8 Beijing, Manila, Perth) 17:30 – 18:30 hours

<b>Moderators: Andrea Doria (Italy), Ronald van Vollenhoven (Netherlands)</b>	
Incorporation of Banff classification in lupus histopathology assessment emphasizes the importance of tubulointerstitial changes <b>Q&amp;A (5 Mins)</b>	<i>Peter Korsten (Germany)</i>
ISG15 deficiency underlie monogenic lupus with inflammatory myositis <b>Q&amp;A (5 Mins)</b>	<i>Lujayn Akbar (Saudi Arabia)</i>
Immunophenotype of systemic lupus erythematosus and Sjögren's syndrome patients identified two endotypes with potential therapeutic implications <b>Q&amp;A (5 Mins)</b>	<i>Lucia Martin-Gutierrez (UK)</i>
Comparison of different definitions of remission in children with lupus nephritis <b>Q&amp;A (5 Mins)</b>	<i>Chiara De Mutis (Italy)</i>
Multi-omic analysis identifies dyslipidaemia in juvenile-SLE patients associated with disease activity, inflammation and atherosclerosis <b>Q&amp;A (5 Mins)</b>	<i>George Robinson (UK)</i>

\*More Posters Available Online

## MEETING HIGHLIGHTS

CET (UTC+2) Paris, Amsterdam, Berlin) 13:00–14:00 hours

EDT (UTC-4 New York, Montreal) 07:00 AM – 08:00 AM

CST (UTC+8 Beijing, Manila, Perth) 19:00 – 20:00 hours

<b>Moderators: Zahir Amoura (France), Richard Furie (USA)</b>	
Meeting Highlights	<i>Eloisa Bonfá (Brazil), David Isenberg (UK), Richard Furie (USA), Zahir Amoura (France)</i>
Questions and Answers (Live)	<i>Steering Committee</i>
<b>Close</b>	<i>Zahir Amoura (France), Richard Furie (USA)</i>



# Programme

## MEET THE EDITOR

CET (UTC+2) Paris, Amsterdam, Berlin) 14:15 – 15:00 hours

EDT (UTC-4 New York, Montreal) 8:15 AM – 9:00 AM

CST (UTC+8 Beijing, Manila, Perth) 20:15 – 21:00 hours

<b>Moderator: Ronald van Vollenhoven (Netherlands)</b>	
Introduction: What is happening in the world of publishing?	<i>Ronald van Vollenhoven (Netherlands)</i>
Workshop: How do I get my manuscript published—in the best possible journal?	
Tips for reviewers: make it work for the authors and yourself	

## PLENARY II: TREATMENT CHALLENGES (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30–17:30 hours

EDT (UTC-4 New York, Montreal) 9:30 AM – 11:30 AM

CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:30 hours

<b>Moderators: Zahir Amoura (France)</b>	
Treatment of CAPS: Which drugs and in which order? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Marc Pineton de Chambrun (France)</i>
Refractory cutaneous lupus: Use of thalidomide or lenalidomide for refractory lupus skin disease <b>Q&amp;A and Discussion (15 Mins)</b>	<i>François Chasset (France)</i>
Osteonecrosis: Prevention and treatment <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Bernardo Pons Estel (Argentina)</i>
Alveolar hemorrhage <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Ricard Cervera (Spain)</i>

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.